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Abstract: Although proton pump inhibitors (PPI) have a record of remarkable effectiveness 
and safety in the management of gastroesophageal reflux disease (GERD), several treatment 
challenges with PPI have emerged. Dexlansoprazole MR is the (R)-enantiomer of lansoprazole 
contained in a formulation that produces two distinct releases of drug and significantly extends the 
duration of active plasma concentrations and % time pH  4 beyond that of conventional single-
release PPI. Dexlansoprazole MR can be administered without regard to meals or the timing of 
meals in most patients. Dexlansoprazole MR 60 mg demonstrated similar efficacy for healing 
of erosive esophagitis at 8 weeks compared with lansoprazole 30 mg, and dexlansoprazole MR 
30 mg was superior to placebo for maintenance of healed erosive esophagitis at 6 months with 
99% of nights and 96% of days heartburn-free over 6 months in patients taking dexlansoprazole 
MR 30 mg. Superior relief of heartburn occurred in patients taking dexlansoprazole MR 30 mg 
(55% heartburn-free 24-hour periods) vs placebo (14%) for symptomatic nonerosive GERD. 
The safety profile of dexlansoprazole MR is similar to that of lansoprazole. The extended 
pharmacodynamic effects, added convenience, and efficacy and safety of dexlansoprazole MR 
offer a novel approach to gastric pH control in patients with acid-related disorders.
Keywords: dexlansoprazole MR, gastroesophageal reflux disease, GERD, erosive esophagitis, 
TAK-390MR
Gastroesophageal reflux disease (GERD) is a clinical condition characterized by persistent 
retrograde movement of gastric contents into the esophagus that typically manifests as 
burning retrosternal pain and/or regurgitation. Atypical symptoms of GERD have been 
described and include chronic cough, vocal hoarseness, globus, waterbrash, and throat 
pain.1 Pharmacologic treatment options for GERD have been directed at suppression of 
gastric acid production in order to reduce both volume and acidity of gastric contents. 
Antisecretory agents employed for the treatment of GERD include the histamine-2 recep-
tor antagonists (H2RA) and proton pump inhibitors (PPI). H2RA possess a rapid onset of 
symptom control and effectively inhibit acid production; however, their use is limited by 
their brief duration of action and tachyphylaxis possibly owing to histamine-2 receptor 
up-regulation and enhanced gastrin secretion in the presence of histamine blockade.2 
In contrast, PPI block the terminal step of acid production via covalent and irreversible 
binding of the protonated moiety of the PPI to cysteine residues on the proton pump, 
thereby rendering it nonfunctional, and its activity cannot be replaced until a new proton 
pump is synthesized. Only active proton pumps are available to be inhibited by PPI, 
and activation is most commonly achieved after ingestion of food. Pentagastrin has also 
been used experimentally to induce proton pump activation.3Clinical and Experimental Gastroenterology 2009:2 118
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A model of proton pump inhibition advanced by Sachs 
proposed that two-thirds of activated proton pumps are 
inhibited by PPI which leaves up to one-third of pumps 
uninhibited and able to secrete acid.4 In addition, not all 
proton pumps are activated by a meal (approximately 
75%), and it is believed that subsequent food intake permits 
activation of dormant pumps which also contributes to acid 
production. Since all PPI share the same mechanism of 
action and have inherently brief half-lives (approximately 
1–2 hours), the potential for activation of proton pumps 
and acid secretion exists after their plasma concentrations 
diminish to subtherapeutic levels. It is important to also 
note that proton pumps are continuously being regenerated 
and the entire population of pumps within the parietal cell 
will typically experience turnover every 48 hours.4,5 Because 
food is the primary stimulus for proton pump activation, 
administration of PPI is commonly recommended a short time 
(60 minutes) before the morning meal, thereby ensuring 
subsequent daytime reduction in basal and meal-stimulated 
acid production.
While PPI have a nearly 20-year record of remarkable 
effectiveness and safety in the management of GERD, 
several treatment challenges with PPI have emerged. 
Symptoms of GERD have been reported to persist in 
between 25 and 40% of patients who take PPI for the 
treatment of erosive esophagitis.6 In particular, nocturnal 
symptoms may predominate in such patients due to persistent 
or de novo proton pump activity. The effectiveness of PPI 
for the treatment of moderate-to-severe erosive esophagitis 
(LA Classification C and D) is less than complete for up to 
25% of patients.7 Even in those who experience complete 
healing of erosive esophagitis, disease relapse rates of up 
to 26% have been described in patients who continue PPI 
therapy.8,9 More than three-fourths of patients with recur-
rent erosive esophagitis are asymptomatic.9 Relapse is 
more precipitous for more severe grades of erosive disease 
(occurring as rapidly as 1 month post-discontinuation of 
medication), but all grades tend to have similarly limited 
durability of healing maintenance at 6 months.8 This finding 
has led the Cochrane Group to recommend full healing doses 
of PPI for maintenance of erosive esophagitis healing.10 
Twice daily off-label administration of PPI is used to remedy 
the inadequacy of PPI effectiveness in nearly one-third 
of patients with GERD,11 especially in order to improve 
overall symptom control and relief of nocturnal heartburn. 
However, the consequence of this practice is increased cost 
of treatment and decreased compliance. Good compliance 
with PPI (defined as 80% fill rate of prescriptions written 
for PPI) resulted in significantly decreased use of the health 
care system and lower health care costs in GERD patients.12 
As a result, perhaps one of the most important drivers of 
PPI effectiveness is patient adherence to therapy regimens. 
Several barriers to full adherence have been reported. Long-
term adherence to once-daily PPI has been shown to decrease 
rapidly over time to approximately 50% of patients reporting 
low or moderate adherence within 3 months of initiation 
which suggests significant intermittent or as-needed use.13 
In addition, the need to take each dose within 60 minutes 
prior to food intake (preferably a full meal in the morning) 
is problematic for many patients who do not eat in the 
morning or who take their dose during or shortly after a 
meal. A survey of patients taking PPI who experienced 
suboptimal benefit revealed that 54% of this group was taking 
their doses incorrectly with approximately equal numbers 
taking the dose on an empty stomach (60 minutes before 
a meal), immediately after ingestion of food, or at bedtime 
(presumably without subsequent food intake).14
Prescribing patterns of PPI are reportedly inconsistent 
with the recommendations of treatment guidelines and 
product labeling with more than one-third of primary 
care providers in one survey responding that the time of 
administration of PPI does not matter, and as many of 29% of 
gastroenterologists failing to address time of administration.15 
The clinical shortcomings of PPI and the barriers to patient 
adherence to therapy have created an unmet medical need 
in the practice of GERD management. The ideal product to 
address these concerns would possess efficacy for erosive 
and nonerosive GERD consistent with the excellent record 
of other PPI, provide extended duration of active drug 
concentrations throughout the day to inhibit proton pumps 
activated by subsequent meals or that are generated later 
in the dosing interval, be administered once daily without 
regard to food intake, and maintain the safety and tolerability 
of the PPI class.
Dexlansoprazole MR: product review
Lansoprazole is a racemic mixture composed of equal 
proportions (50:50) of (R)-lansoprazole (also known as 
dexlansoprazole) and (S)-lansoprazole. These two enantiomers 
have been quantified separately in blood after ingestion 
of lansoprazole 30 mg in healthy volunteers and it was 
found that the mean maximum plasma concentration (Cmax) 
and area under the plasma drug concentration-time curve 
(AUC) values were 3- to 5-fold greater for dexlansoprazole 
than (S)-lansoprazole.16 This suggests that the hepatic 
clearance of lansoprazole is stereoselective in favor Clinical and Experimental Gastroenterology 2009:2 119
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of the (S) enantiomer leading to higher systemic exposure 
of and in vivo residence for dexlansoprazole as compared 
to its antipode, (S)-lansoprazole. Dexlansoprazole is highly 
bound to plasma proteins (96.1%–98.8% bound) and has an 
apparent volume of distribution of 40.3 L in subjects with 
GERD.17 The elimination of dexlansoprazole is via the hepatic 
route; biotransformation to oxidative metabolites occurs 
via CYP2C19 and CYP3A4 with subsequent conjugation 
to inactive products and elimination in the urine and feces. 
In vitro data suggest that CYP2C19 displays more specificity 
for R- than S-lansoprazole, and that CYP3A4 is more specific 
for S-lansoprazole.18 Dexlansoprazole does not appear to be 
eliminated unchanged in the urine.
The elimination half-life of dexlansoprazole is approxi-
mately 1–2 hours in healthy subjects and in patients with 
symptomatic GERD; this is similar to other PPI. The Dual 
Delayed Release formulation (DDR™) employed in delivering 
dexlansoprazole is a more significant factor in prolonging 
drug residence time in the body after oral administration 
than the inherently slower clearance of dexlansoprazole 
as compared to the (S)-enantiomer. The DDR formulation 
delivers 2 drug inputs in the proximal and more distal small 
intestine. Distinct pH-dependent releases of drug are designed 
to occur from two types of enteric-coated granules housed in 
a gelatin capsule. Upon dissolution of the outer capsule in the 
stomach, the first type of granule is designed to release quickly 
after the granules reach the proximal duodenum providing 
an initial drug release profile similar to that of lansoprazole 
and resulting in an initial peak in plasma dexlansoprazole 
concentrations within 1 to 2 hours of capsule ingestion. The 
second release from the remaining granules is designed to 
release farther along the gastrointestinal tract at the distal 
portion of the small intestine and creates a second drug peak 
in plasma dexlansoprazole concentrations within 4 to 5 hours 
of capsule ingestion. The purpose of the second release is 
to provide a greater amount of drug to be absorbed later in 
the dosing interval in order to provide extended duration of 
acid suppression. Therefore, the resulting time-concentration 
profile of dexlansoprazole MR reveals a two-peaked pattern 
that extends to approximately 12 hours after a dose is ingested 
(Figure 1).
The relationship between exposure of dexlansoprazole 
following administration of dexlansoprazole MR and its 
pharmacodynamic effect measured as intragastric pH has been 
described using an Emax model.19 A total of 83 healthy subjects 
met the entry criteria for 2 studies, and were included in this 
combined analysis. Subjects were administered 30, 60, 90, 
and 120 mg of dexlansoprazole MR in randomized crossover 
fashion in these two separate studies. The systemic exposure 
of dexlansoprazole measured as Cmax and AUC values 
was dose-proportional and time-independent. These two 
pharmacokinetic and pharmacodynamic studies confirmed 
that the DDR™ technology used in the dexlansoprazole MR 
formulation prolonged drug exposure; pharmacokinetic and 
pharmacodynamic modeling suggested that doses lower than 
30 mg may result in therapeutically suboptimal intragastric 
pH control. Furthermore, it was demonstrated that doses 
higher than 90 mg would be unlikely to provide additional 
clinically meaningful pharmacologic response.
In a retrospective analysis using data from 2 separate 
but similarly designed studies the pharmacokinetic profiles 
of dexlansoprazole MR 60 mg and lansoprazole 60 mg 
were compared after 5 days of dosing in healthy volunteers, 
demonstrating that the tmax for both regimens occurred 
1 to 2 hours after administration, and that the second 
peak for dexlansoprazole MR occurred 4 to 5 hours after 
administration.20 The results from this single post-hoc analysis 
also showed that the mean residence time for dexlansoprazole 
MR was nearly double that of lansoprazole at equivalent doses 
of 60 mg once daily (5.5 hours vs 2.9 hours, respectively).21
The pharmacokinetics, pharmacodynamics, and safety 
of three dosing regimens of dexlansoprazole MR (60, 90, 
and 120 mg) and lansoprazole 30 mg were assessed in 
an open-label, multiple-dose, single-center, four-period, 
crossover study in 40 subjects.22 After 5 days of once 
daily administration dexlansoprazole MR 60 mg produced 
statistically significantly greater mean 24-hour intragastric 
pH compared to lansoprazole 30 mg (4.55 vs 4.13, 
respectively, P  0.001); a statistically significant increase 
in % time 24-hour intragastric pH  4 was also observed 
(71% vs 60% , respectively, P  0.01) (Figure 2). The 90 mg 
dose of dexlansoprazole MR produced 24-hour intragastric 
pH  4 for 70% of the time. The pharmacodynamic effect 
of dexlansoprazole MR 120 mg was similar to that of the 
90 mg dose. As a result, the 120 mg dose was not pursued 
for clinical development. The clinical significance of these 
differences remains unknown, but the DDR™ formulation of 
dexlansoprazole MR appears to provide pharmacodynamic 
benefit beyond that of lansoprazole most likely due to the 
extended duration of effective plasma concentration.
The impact of food on the pharmacokinetics and 
pharmacodynamics of dexlansoprazole MR was evaluated 
in 46 healthy subjects who completed all dosing regimens 
in a randomized, 4-period, open-label, crossover study.23 
Placebo was administered in 4 regimens: after a 10-hour 
fast, 30 minutes before, 5 minutes before, or 30 minutes after Clinical and Experimental Gastroenterology 2009:2 120
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TAK-390MR 60 mg QD
TAK-390MR 30 mg QD
TAK-390MR 90 mg QD
TAK-390MR 60 mg QD
TAK-390MR 120 mg QD
Lansoprazole 30 mg QD
Lansoprazole 15 mg QD
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Figure 1 Mean time-concentration profiles of dexlansoprazole MR on Day 5.   Adapted by permission from Informa Healthcare  Vakily M, Zhang W, Wu J,   Atkinson SN, Mulford D. 
Pharmacokinetics and pharmacodynamics of a known active PPi with a novel dual delayed release technology, dexlansoprazole Mr: a combined analysis of randomized controlled 
clinical trials. Curr Med Res Opin. 2009;25(3):627–638.19 Copyright © 2009.
a high-fat breakfast on Day 1; dexlansoprazole MR 90 mg 
was administered in the same fashion for each crossover 
period on Day 3. Plasma concentrations of dexlansoprazole 
were measured on Day 3 and 24-hour intragastric pH was 
assessed on Days 1 and 3. Pharmacokinetics of dexlanso-
prazole in the fed conditions (administered 5 minutes before 
and 30 minutes after a high-fat breakfast) when compared to 
the fasted state displayed at least a 1.09-fold greater increase 
(using the point estimates) in Cmax and AUC for the fed state 
(Figure 3). Thus, the bioavailability was increased in the 
fed vs fasted state. The data also showed that the systemic 
exposure of dexlansoprazole after dexlansoprazole MR was 
administered 30 minutes before a high-fat breakfast was 
bioequivalent to that obtained following administration of 
dexlansoprazole MR under fasted state. The differences in 
the pharmacodynamic parameters measured as mean 24-hour 
intragastric pH and % time 24-hour intragastric pH  4 were 
not considered to be clinically meaningful between any of 
the periods which signified both a lack of food effect and a 
lack of effect of timing of food intake relative to dosing with 
dexlansoprazole MR on intragastric pH profile.
Because PPI are traditionally administered before the 
morning meal, it is important to determine if a PPI with 
extended release properties such as dexlansoprazole MR can 
be taken at different times during the day which may offer 
greater dosing flexibility. The influence of time of day of Clinical and Experimental Gastroenterology 2009:2 121
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dexlansoprazole MR administration on pharmacokinetic and 
pharmacodynamic variables was assessed in 44 healthy sub-
jects who completed all regimens in a 4-period, randomized, 
crossover fashion in which drug was administered daily for 
five days 30 minutes before breakfast, lunch, dinner, or a 
bedtime snack. Plasma drug concentrations and 24-hour 
intragastric pH were assessed on Day 5 of each period.24 
Systemic exposure of dexlansoprazole when dosed before 
breakfast was bioequivalent when dosed before lunch, dinner 
or an evening snack, and minimal but statistically significant 
differences were found in mean 24-hour intragastric pH 
between dosing at breakfast and at lunch (0.2 difference in pH) 
and in % time 24-hour intragastric pH  4 between dosing 
at breakfast and at bedtime snack (7% difference). No other 
significant differences in 24-hour intragastric pH were found 
between breakfast and the other mealtimes. Therefore, the 
dosing versatility of dexlansoprazole MR appears to extend 
beyond the lack of an effect by food into the realm of dose 
timing flexibility.
The impact of dose timing on the pharmacodynamic 
effects of other PPI has been previously studied. Rabeprazole 
dose timing was studied in a crossover fashion in 20 GERD 
patients, and a significantly greater % time intragastric pH  4 
was observed when the dose was given once daily in the 
morning vs the evening.25 Dosing lansoprazole in the morning 
produced no differences in intragastric pH (mean 24-h 
pH or % time pH  4) than evening dosing in healthy subjects 
in one study.26 However, morning dosing of lansoprazole in 
another study was significantly more effective than evening 
dosing at intragastric pH control for all time periods during 
the day except for overnight, when the two dosing methods 
were comparable.27
An alternative method of dexlansoprazole administration 
was studied in 50 healthy subjects in a two-period, 
randomized, crossover study where dexlansoprazole MR 
90 mg was ingested after a 10-hour fasting period as either an 
intact capsule with water or after the capsule was opened and 
the granules were sprinkled over applesauce and swallowed.28 
No significant differences in either AUC or Cmax were found 
between the two methods, and bioequivalence was established 
for dexlansoprazole MR regardless of whether given whole 
with water or sprinkled over applesauce.
Drug–drug interactions remain a potential concern for 
any compound that undergoes extensive hepatic metabolism, 
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including PPI. Four separate studies were conducted in 
healthy subjects in which dexlansoprazole MR 90 mg was 
given once daily for 9 to 11 days with a single dose of a test 
substrate. The test substrates for the in vivo assessment of 
CYP enzyme activity included diazepam 5 mg (a substrate 
for CYP2C19 and CYP3A), phenytoin 250 mg (CYP2C9 and 
CYP2C19), theophylline (given as intravenous aminophylline 
400 mg, CYP1A2), and warfarin 25 mg (CYP2C9).29 No 
significant differences in Cmax or AUC of any substrate were 
detected when given concomitantly with dexlansoprazole 
MR. Furthermore, the pharmacodynamic impact of 
coadministration of dexlansoprazole MR with warfarin as 
measured by change in INR was not significant. Therefore, 
no significant pharmacokinetic and pharmacodynamic 
(for warfarin only) drug–drug interactions were found in 
these studies with dexlansoprazole MR. At the time of this 
review no studies have been conducted with dexlansoprazole 
and clopidogrel, so the effect of the two drugs when given 
together is unknown.
Due to complete metabolism in the liver to inactive 
metabolites and the absence of unchanged drug excreted in 
the urine, dexlansoprazole MR is not expected to undergo 
accumulation in kidney dysfunction, and no dose adjustment 
is required in patients with renal impairment.
Accumulation of dexlansoprazole concentrations 
occurred in subjects with moderate (Child Pugh Class B) 
hepatic impairment, but not in mild impairment (Child Pugh 
Class A).30 Due to this finding, studies were not conducted 
in patients with severe hepatic impairment. Thus, the lower 
dexlansoprazole MR dose of 30 mg should be considered in 
moderate hepatic impairment, and no dosage adjustment is 
required in mild impairment.
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Dexlansoprazole MR pharmacokinetics were not 
significantly altered in elderly patients,31 women,31 or GERD 
patients.32
Dexlansoprazole MR: clinical studies
The clinical development program for dexlansoprazole MR 
was the largest for any PPI to date and comprised 6 pivotal 
studies in more than 4500 patients. The goals of this program 
were to establish the efficacy and safety of dexlansoprazole 
MR in the treatment and maintenance of erosive esophagitis 
and in the control of symptomatic nonerosive GERD.
Healing of erosive esophagitis
Two identically designed trials evaluated the efficacy and 
safety of dexlansoprazole MR vs lansoprazole in the healing 
of erosive esophagitis.33 Both trials were randomized and 
double-blinded and compared dexlansoprazole MR 60 mg 
and 90 mg with lansoprazole 30 mg once daily. All doses 
were given once daily within 60 minutes of the morning 
meal to maintain blinding, and the duration of treatment 
was 8 weeks. All patients were adults (age 18 years) with 
endoscopically proven erosive esophagitis. Exclusion criteria 
included the presence of Helicobacter pylori infection or 
Barrett’s esophagus. Esophagogastroduodenoscopy (EGD) 
was performed at baseline (to establish the presence of 
esophageal erosions) and at 4 and 8 weeks. The primary 
endpoint was the percentage of patients with endoscopic 
evidence of healing at 8 weeks, and secondary endpoints 
included the percentage of subjects with moderate-to-severe 
(Los Angeles [LA] Grades C and D) erosive esophagitis who 
were healed at 8 weeks, and all grades healed at 4 weeks. 
The target proportion of patients with LA Grade C and D 
disease was 30% as consistent with FDA guidance that this 
subgroup of disease presents specific challenges to healing. 
The symptoms of erosive esophagitis were recorded by diary 
twice daily: upon awakening each morning to capture any 
symptoms experienced overnight and upon retiring each 
evening to capture any symptoms experienced while awake. 
The rigor of this recording method was intended to minimize 
the recall bias that may arise from once daily symptom 
recording. The primary method of analysis of the healing 
rate was the crude rate; this analysis method classifies any 
subject who does not complete the study (eg, no data for 
week 8 endoscopy) as a complete treatment failure. This is 
in contrast to life-table analysis, the statistical methodology 
historically used in PPI trials, in which the probability is 
calculated that a patient would have healed had he remained 
in the study and received the final EGD. As such, in life-table 
analysis the patient who does not complete the trial is 
considered a partial failure. The crude rate is an inherently 
more stringent analysis method, and typically yields lower 
healing rates than life-table. Both dexlansoprazole MR 
erosive esophagitis healing trials were designed to test for 
noninferiority; the dexlansoprazole MR doses shown to be 
noninferior were then tested for superiority to lansoprazole 
30 mg for primary and secondary efficacy endpoints. For 
each study, a sample size of 520 patients per treatment group 
provided at least 95% power at the 0.025 level of signifi-
cance to detect noninferiority between dexlansoprazole MR 
and lansoprazole, assuming equal healing rates of 87% at 
Week 8.
Baseline demographics were not significantly different 
between any of the groups in either study. Erosive 
esophagitis healing rates at week 8 for both dexlansopra-
zole MR doses were superior to lansoprazole in one study 
(Study 1); 60 mg of dexlansoprazole MR was noninferior 
and 90 mg was superior to lansoprazole in the other study 
(Figure 4). Healing at week 4 was 64% for all groups using 
both crude rate and life-table analysis methods. Healing of 
moderate-to-severe erosive esophagitis was significantly 
greater with dexlansoprazole MR 60 mg than lansoprazole 
in Study 1 and both doses were noninferior to lansoprazole 
in Study 2. The median percentage of 24-hour heartburn-
free days was greater than 80% in patients who received 
either dose of dexlansoprazole MR; this was comparable 
to lansoprazole.
Maintenance of erosive  
esophagitis healing
Subjects who experienced healing of erosive esophagitis in 
either of the two healing studies mentioned previously were 
eligible for enrollment in one of two studies designed to 
evaluate the maintenance of healing over a 6-month period. 
One study compared dexlansoprazole MR 30 mg and 60 mg 
with placebo34 and the other study compared 60 mg and 90 mg 
doses with placebo.35 The placebo-controlled design was 
consistent with the standard comparator of other esophagitis 
healing maintenance studies. The final endoscopy of the pre-
vious healing study was considered the baseline assessment 
of healing for this maintenance study and was followed by 
endoscopies at 1, 3, and 6 months to document persistence 
of healing. The primary efficacy endpoint was the percent-
age of subjects who maintained healed erosive esophagitis 
at 6 months. Secondary efficacy endpoints included the 
percentage of days without daytime or nighttime heartburn 
and the percentage of nights without heartburn. Symptoms Clinical and Experimental Gastroenterology 2009:2 124
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were recorded by subjects twice daily in a manner identical 
to the erosive esophagitis healing studies.
The enrollment of the study that compared dexlansoprazole 
MR 30 mg and 60 mg with placebo was 445 subjects, 
and the withdrawal rate from study medication was 83% 
for the placebo group and 34% for each dexlansoprazole 
MR group, mostly due to relapse of erosive esophagitis. 
Maintenance of healing rates were significantly higher for both 
dexlansoprazole MR doses compared to placebo, and this find-
ing was consistent for all grades of erosive esophagitis and for 
moderate-to-severe disease. The median percentage of 24-hour 
heartburn-free days and median percentage of nights without 
heartburn was statistically significantly higher for all doses 
of dexlansoprazole MR than placebo, with 96% of 24-hour 
periods and 99% of nights being reported as heartburn-free 
over 6 months for dexlansoprazole MR 30 mg vs 29% of 
24-hour periods and 72% of nights for placebo (Figure 5).
Symptomatic relief of nonerosive GErD
The control of nonerosive GERD symptoms remains 
a therapeutic challenge for practitioners, because the 
true etiology of the symptoms may or may not be due to acid 
or may be unknown. A clinical trial compared two different 
doses of dexlansoprazole MR (30 and 60 mg) with placebo in 
subjects with normal esophageal mucosa on EGD.36 This study 
identified patients with heartburn-predominant complaints 
for at least 6 months and for 4 of the 7 days prior to screening 
for enrollment, but no minimal severity of symptoms 
was required. Besides EGD, no objective assessments of 
esophageal disease such as pH-metry were conducted and 
no attempts were made to identify or exclude patients with 
functional heartburn. Study medication was administered 
in a blinded fashion once daily in the morning for 28 days. 
Subjects recorded heartburn symptom assessments twice 
daily as described for the erosive esophagitis healing and 
maintenance studies, and investigator assessments occurred 
at baseline and at 2 and 4 weeks of the study. The primary 
endpoint was the percentage of 24-hour periods that were 
free of heartburn symptoms over 28 days, and the secondary 
endpoint was the percentage of daytime periods and nighttime 
periods without heartburn. The results demonstrated that a 
majority of the 24-hour periods were heartburn-free in the 
groups that received dexlansoprazole MR (median percentage 
54.9% for the 30 mg group) compared with 18.5% for the 
placebo group (Figure 6). The dexlansoprazole MR 30 mg 
group also experienced significantly greater nighttime 
periods (median percentage of nights 80.8% vs 51.7% for 
placebo) and daytime periods (median percentage of days 
63.0% vs 26.9% for placebo) that were symptom-free. It is 
important to note that no nighttime symptom requirement 
was necessary for enrollment into the study; this may 
partially explain the relatively large placebo response for this 
endpoint. The percentage of patients during the study who 
experienced 24-hour heartburn-free days over the first 3 days 
of treatment was significantly greater for dexlansoprazole 
MR treatment groups than placebo. The percentage of 
patients with 24-hour heartburn-free days by each study day 
is presented in Figure 7.
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Dexlansoprazole MR: safety  
and tolerability
The safety and tolerability of dexlansoprazole MR was 
evaluated in more than 4500 patients in seven trials of the 
phase 3 clinical development program. Treatment-emergent 
adverse events were reported in which any such event 
that occurred after the ingestion of the first dose of study 
medication was recorded and analyzed. The strictness of 
this reporting method contrasts with reporting of treatment-
related events which requires the investigator to deem an Clinical and Experimental Gastroenterology 2009:2 126
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adverse event to be related to the study medication in order 
to be reported. The most commonly reported treatment-
emergent adverse events (with a frequency of 2%) from 
all clinical studies of dexlansoprazole MR are presented 
in Table 1. Diarrhea was the most common adverse event 
leading to discontinuation form dexlansoprazole therapy in 
controlled clinical studies (0.7%).20
The elevation of plasma gastrin concentrations by PPI is 
a well-established class effect that is due to the compensatory 
increase in afferent hormonal input of parietal cell acid 
production. The trophic effects of gastrin on the gastric 
mucosa and evidence of ECL-cell hyperplasia in animals 
have led to potential controversy about the long-term use 
of PPI in humans. Mean plasma gastrin AUC24 increased 
by approximately 3.5-fold compared with baseline values 
after 5 days of dosing with dexlansoprazole MR 90 mg or 
120 mg; this magnitude of increase was similar to that of 
lansoprazole 30 mg in a crossover study in healthy subjects.37 
Gastrin parameters started to decline within 3 days after 
drug discontinuation, and returned to baseline within 7 days 
after the last dose of drug. Thus, the changes in gastrin 
associated with dexlansoprazole MR appeared to be modest, 
reversible, unrelated to dose, and similar to other PPI. 
Elevations in serum gastrin concentrations were higher in the 
dexlansoprazole MR groups than in the lansoprazole group 
in the erosive esophagitis healing studies, but were within 
the expected range for PPI.33 Gastrin elevations also occurred 
in all dexlansoprazole MR groups in the maintenance and 
nonerosive GERD studies compared to placebo.34,36 These 
elevations were also within the range expected for patients 
receiving PPI.
Gastric biopsies obtained at the final visit in patients 
enrolled in either of the maintenance of erosive esophagitis 
studies revealed no findings of neuroendocrine cell 
proliferation or adenocarcinoma.34,35
Finally, no changes in the cardiac rhythm (including 
Q-T interval) were detected in healthy volunteers who 
received a single dose of dexlansoprazole MR 90 mg or 
300 mg.38 No consistent, clinically important changes in 
laboratory results, vital signs, or physical examinations 
were observed.
Summary and conclusions
Dexlansoprazole MR is a PPI administered by a unique 
delivery system that extends the duration of active plasma 
concentrations of drug beyond conventional PPI. It is 
available in two dosage strengths, 30 and 60 mg, and is 
currently approved for 3 clinical indications: healing of 
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erosive esophagitis at a dose of 60 mg orally once daily for 
up to 8 weeks, maintenance of erosive esophagitis healing 
at a dose of 30 mg orally once daily for up to 6 months, and 
relief of symptomatic nonerosive GERD at a dose of 30 mg 
orally once daily for 4 weeks. In 2 large active-control 
studies of dexlansoprazole MR it showed healing rates of all 
grades of erosive esophagitis consistent with lansoprazole, 
and this healing was maintained for up to 6 months in nearly 
two-thirds of patients at either dose in another placebo-
controlled study. In addition, dexlansoprazole MR provided 
complete relief of heartburn symptoms for a median of 55% 
of 24-hour periods over 28 days in patients with symptomatic 
nonerosive GERD. The safety profile of dexlansoprazole MR 
is similar to that of lansoprazole. Because dexlansoprazole 
MR can be taken without regard to food or time of day it is 
more convenient for individuals who find compliance with 
meal-associated dosing of medication difficult or eat at 
irregular times. The prolonged duration of acid suppression 
provided by dexlansoprazole MR addresses the short half-life 
of conventional PPI and offers a novel approach to extending 
gastric pH control in patients with selected acid-related 
disorders.
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